{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-077410","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.958625+00:00","generated_at":"2026-06-13T13:29:01.750880+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvectis Pharma reports $24.5M cash, runway into H1 2025","bullets":["Cash and equivalents of $24.5M at June 30, 2023, up ~$9.0M from March 31, 2023.","Increase primarily from exercise of previously issued preferred investment options in Q2 2023.","Company estimates current cash sufficient to fund planned operations into first half of 2025.","Cash figure is preliminary, subject to change upon completion of period-end close."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-077410","json":"https://secwatch.observer/filing/0001104659-23-077410.json","markdown":"https://secwatch.observer/filing/0001104659-23-077410.md","text":"https://secwatch.observer/filing/0001104659-23-077410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923077410/0001104659-23-077410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923077410/tm2320415d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T13:29:01.750880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}